In an advance in the emerging field of bacterial imaging, scientists are reporting development of a method for identifying specific sites of localized bacterial infections in living animals. Bradley D. Smith at the University of Notre Dame and colleagues describe the method in a report scheduled for the Jan. 10 edition of the Journal of the American Chemical Society, a weekly publication.
New research reveals that while cholesterol-lowering drugs do increase the risk of painful inflammation of the pancreas, the side effect is relatively rare, according to Sonal Singh, M.D., from Wake Forest University School of Medicine, and colleagues.
A humanized mouse model may be valuable for not only studying sex differences in RA, but also for understanding why women are particularly vulnerable to autoimmunity and for developing future therapeutic strategies.
Recent studies show promise for significantly reducing vascular aging by inactivating TNF?, which has been linked to blood vessel dysfunction and cell death. The related report by Csiszar et al., “Vasculoprotective effects of anti-TNF? treatment in aging,” appears in the January issue of The American Journal of Pathology.
One key to your high blood pressure might just be your inflammatory genes. It may sound odd but mounting evidence suggests that inflammation, a part of the immune response implicated in diseases such as cancer, Alzheimer’s and diabetes, may also help translate stress into high blood pressure.
The Food and Drug Administration (FDA) today approved Colazal (balsalazide disodium) for the treatment of mildly to moderately active ulcerative colitis in patients 5 to 17 years of age.
A new, large survey supported by the Crohn’s & Colitis Foundation of America (CCFA) finds that 65 percent of ulcerative colitis patients are less than fully compliant with first-line therapies to treat their disease.The most commonly reported reasons for noncompliance with medications were the dosing frequency, the number of pills and the inconvenience associated with the medication.
Right now there’s no rapid way to diagnose sepsis, a fast-moving blood infection that is a leading cause of death in hospital intensive care units. New research at Washington University School of Medicine in St. Louis suggests that doctors one day could quickly distinguish sepsis from widespread non-infectious inflammation based on genetic profiles of patients’ blood.
A comprehensive survey of the serologic proteome in human SLE suggests that severely disrupted chemokine gradients may contribute to the systemic autoimmunity observed.
The U.S. Food and Drug Administration (FDA) today approved Celebrex (celecoxib) for a new use ? the relief of the signs and symptoms of Juvenile Rheumatoid Arthritis (JRA) in patients two years of age and older. Today’s approval follows the November 29 meeting of FDA’s Arthritis Advisory Committee, in which the committee voted 15 to 1 in favor of approval of this product.